Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the MRC Weatherall Institute of Molecular Medicine have developed a new platform based on CRISPR/Cas9 technology, to alter the way human cells respond to external signals.

Cells are constantly monitoring the environment around them and are programmed to respond to molecular cues in their surroundings in distinct ways – some cues may prompt cells to grow, some lead to cell movement and others initiate cell death. For a cell to remain healthy, these responses must be finely balanced. It took evolution over two billion years to tune these responses and orchestrate their interplay in each and every human cell. But what if we could alter the way our cells respond to certain aspects of their environment? Or make them react to signals that wouldn’t normally provoke a reaction? New research published by scientists at the MRC WIMM takes cellular engineering to the next level in order to achieve just that.

In a paper published in Cell Reports, graduate student Toni Baeumler and Associate Professor Tudor Fulga (Radcliffe Department of Medicine) have used a derivative of the CRISPR/Cas9 technology to rewire the way cells respond to extracellular signals. CRISPR/Cas9 frequently makes the headlines as it allows medical researchers to accurately manipulate the human genome – opening up new possibilities for treating diseases. These studies often focus on correcting faulty genes in crops, livestock, mammalian embryos or cells in a dish. However, not all diseases are caused by a defined error in the DNA. In more complex disorders like diabetes and cancer, it may be necessary to completely rewire the way in which cells work.

Read more on the Oxford Science Blog.

Similar stories

New Associate Professor appointments announced

Congratulations to Dr Bethan Psaila, Dr Benjamin Fairfax, Dr Hashem Koohy, Dr Andrew Blackford and Dr Oliver Bannard who have all been awarded the title of Associate Professor in recognition of their research achievements, contribution to teaching and contributions to the Medical Sciences Division.

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.